切换至 "中华医学电子期刊资源库"
高级检索
中华损伤与修复杂志(电子版)

中华损伤与修复杂志(电子版) ›› 2022, Vol. 17 ›› Issue (06) : 524 -530. doi: 10.3877/cma.j.issn.1673-9450.2022.06.011

综述

鲍曼不动杆菌在烧伤患者中的流行性及其耐药机制的研究进展
廖武强1, 刘金晶2, 胡时强3, 张红艳3, 毛远桂3, 涂家金4,†()   
  1. 1. 330006　南昌大学江西医学院第一临床医学院；330006　南昌大学第一附属医院烧伤科
    2. 330006　南昌大学江西医学院第一临床医学院；341000　赣州市人民医院创伤急救中心
    3. 330006　南昌大学第一附属医院烧伤科
    4. 341000　赣州市人民医院创伤急救中心
  • 收稿日期:2022-09-16 出版日期:2022-12-01
  • 通信作者: 涂家金

Research progress on the prevalence of Acinetobacter baumannii in burn patients and its drug resistance mechanism

Wuqiang Liao1, Jinjing Liu2, Shiqiang Hu3, Hongyan Zhang3, Yuangui Mao3, Jiajin Tu4,†()   

  1. 1. First Clinical Medical College, Jiangxi Medical College, Nanchang University, Nanchang 330006, China; Department of Burn, First Affiliated Hospital of Nanchang University, Nanchang 330006, China
    2. First Clinical Medical College, Jiangxi Medical College, Nanchang University, Nanchang 330006, China; Trauma Emergency Center, Ganzhou People′s Hospital, Ganzhou 341000, China
    3. Department of Burn, First Affiliated Hospital of Nanchang University, Nanchang 330006, China
    4. Trauma Emergency Center, Ganzhou People′s Hospital, Ganzhou 341000, China
  • Received:2022-09-16 Published:2022-12-01
  • Corresponding author: Jiajin Tu
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

廖武强, 刘金晶, 胡时强, 张红艳, 毛远桂, 涂家金. 鲍曼不动杆菌在烧伤患者中的流行性及其耐药机制的研究进展[J]. 中华损伤与修复杂志(电子版), 2022, 17(06): 524-530.

Wuqiang Liao, Jinjing Liu, Shiqiang Hu, Hongyan Zhang, Yuangui Mao, Jiajin Tu. Research progress on the prevalence of Acinetobacter baumannii in burn patients and its drug resistance mechanism[J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2022, 17(06): 524-530.

近年来随着抗生素在临床上的大量应用，烧伤感染患者中鲍曼不动杆菌(Ab)感染率呈逐渐上升的趋势，且多重耐药情况日趋严重，对Ab耐药机制的研究成为当前的热门课题。但因其机制错综复杂，到目前为止尚未达成共识。本文从Ab的毒力因子、在烧伤患者中的流行性、对临床常用药物的耐药情况及最近国内外学者对常见抗生素包括β-内酰胺类、氨基糖苷类、四环素类等的耐药机制研究成果作一综述。

关键词: 鲍氏不动杆菌, 感染, 多重耐药, 毒力因子, 抗生素

In recent years, with the extensive application of antibiotics in clinic, the infection rate of Acinetobacter baumannii (Ab) in patients with burn infection is gradually increasing, and the situation of multiple drug resistance is becoming more and more serious. The research on the mechanism of drug resistance of Ab has become a hot topic. However, because of its complex mechanism, no consensus has been reached so far. This article reviews the virulence factors of Ab, its prevalence in burn patients, drug resistance to commonly used clinical drugs, and recent domestic and foreign scholars on the resistance mechanisms of common antibiotics including β-lactam, aminoglycosides, tetracyclines, etc.

Key words: Acinetobacter baumannii, Infection, Multidrug resistance, Virulence factors, Anti-bacterial agents
[1]
黎鳌，杨宗城. 黎鳌烧伤学[M]. 上海：上海科学技术出版社，2001: 67-80.
[2]
张成，彭源，罗小强，等. 3067例住院烧伤患儿流行病学调查及其感染的病原学特征分析[J]. 中华烧伤杂志，2021, 37(6): 538-545.
[3]
Tchakal-Mesbahi A, Abdouni MA, Metref M. Prevalence Of Multidrug-Resistant Bacteria Isolated From Burn Wounds In Algeria[J]. Ann Burns Fire Disasters, 2021, 34(2): 150-156.
[4]
Harding CM, Hennon SW, Feldman MF. Uncovering the mechanisms of Acinetobacter baumannii virulence[J]. Nat Rev Microbiol, 2018, 16(2): 91-102.
[5]
Kaushik V, Tiwari M, Joshi R, et al. Therapeutic strategies against potential antibiofilm targets of multidrug-resistantAcinetobacter baumannii[J]. J Cell Physiol, 2022, 237(4): 2045-2063.
[6]
王丽英，王凌峰. 鲍曼不动杆菌生物膜耐药机制及防治进展[J/CD]. 中华临床医师杂志(电子版), 2014, 8(5): 970-974.
[7]
刘薇，程翔，梁玉龙，等. 不同烧伤面积患者创面感染病原菌分布及其耐药性[J]. 中国感染控制杂志，2022, 21(1): 30-36.
[8]
徐优耀，张桂华，刘莹. 烧伤住院患者感染病原菌的分布及耐药性分析[J]. 中国冶金工业医学杂志，2022, 39(2): 217-218.
[9]
宋均辉，夏正国，黄庆，等. 烧伤病房内小儿烧伤创面感染病原菌调查及抗生素敏感性分析[J/CD]. 中华损伤与修复杂志(电子版), 2019, 14(1): 46-51.
[10]
丁华荣，胡加平，李德绘，等. 烧伤整形外科1963株细菌及其耐药情况分析[J]. 广西医科大学学报，2019, 36(1): 102-106.
[11]
常璠，纪荣祖，朱宏伟，等. 2014-2018年某院烧伤患者感染细菌分布及耐药性分析[J]. 中外医学研究，2019, 17(29): 69-72.
[12]
De Oliveira DMP, Forde BM, Kidd TJ, et al. Antimicrobial Resistance in ESKAPE Pathogens[J]. Clin Microbiol Rev, 2020, 33(3): e00181-119.
[13]
Pulingam T, Parumasivam T, Gazzali AM, et al. Antimicrobial resistance: Prevalence, economic burden, mechanisms of resistance and strategies to overcome[J]. Eur J Pharm Sci, 2022, 170: 106103.
[14]
刘秋萍，徐凌. 鲍曼不动杆菌耐药机制的研究进展[J]. 中国抗生素杂志，2018, 43(10): 1179-1187.
[15]
Vrancianu CO, Gheorghe I, Czobor IB, et al. Antibiotic Resistance Profiles, Molecular Mechanisms and Innovative Treatment Strategies of Acinetobacter baumannii[J]. Microorganisms, 2020, 8(6)：935.
[16]
Sloczynska A, Wand ME, Tyski S, et al. Analysis of blaCHDL Genes and Insertion Sequences Related to Carbapenem Resistance in Acinetobacter baumannii Clinical Strains Isolated in Warsaw, Poland[J]. Int J Mol Sci, 2021, 22(5): 2486.
[17]
Hawkey J, Ascher DB, Judd LM, et al. Evolution of carbapenem resistance in Acinetobacter baumannii during a prolonged infection[J]. Microb Genom, 2018, 4(3): e000165.
[18]
Zhong X, Wu X, Schweppe DK, et al. In Vivo Cross-Linking MS Reveals Conservation in OmpA Linkage to Different Classes of β-Lactamase Enzymes[J]. J Am Soc Mass Spectrom, 2020, 31(2): 190-195.
[19]
Zhu LJ, Chen XY, Hou PF. Mutation of CarO participates in drug resistance in imipenem-resistantAcinetobacter baumannii[J]. J Clin Lab Anal, 2019, 33(8): e22976.
[20]
Yaghi J, Fattouh N, Akkawi C, et al. Unusually High Prevalence of Cosecretion of Ambler Class A and B Carbapenemases and Nonenzymatic Mechanisms in Multidrug-Resistant Clinical Isolates ofPseudomonas aeruginosa in Lebanon[J]. Microb Drug Resist, 2020, 26(2): 150-159.
[21]
Leus IV, Weeks JW, Bonifay V, et al. Substrate Specificities and Efflux Efficiencies of RND Efflux Pumps of Acinetobacter baumannii[J]. J Bacteriol, 2018, 200(13): e00049-18.
[22]
Garneau-Tsodikova S, Labby KJ. Mechanisms of resistance to aminoglycoside antibiotics: overview and perspectives[J]. Medchemcomm, 2016, 7(1): 11-27.
[23]
Kishk R, Soliman N, Nemr N, et al. Prevalence of Aminoglycoside Resistance and Aminoglycoside Modifying Enzymes in Acinetobacter baumannii Among Intensive Care Unit Patients, Ismailia, Egypt[J]. Infect Drug Resist, 2021, 14: 143-150.
[24]
Xu C, Bilya SR, Xu W. adeABC efflux gene in Acinetobacter baumannii[J]. New Microbes New Infect, 2019, 30: 100549.
[25]
Lee CR, Lee JH, Park M, et al. Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options[J]. Front Cell Infect Microbiol, 2017, 7: 55.
[26]
Beabout K, Hammerstrom TG, Perez AM, et al. The ribosomal S10 protein is a general target for decreased tigecycline susceptibility[J]. Antimicrob Agents Chemother, 2015, 59(9): 5561-5566.
[27]
Hua X, He J, Wang J, et al. Novel tigecycline resistance mechanisms in Acinetobacter baumannii mediated by mutations in adeS, rpoB and rrf[J]. Emerg Microbes Infect, 2021, 10(1): 1404-1417.
[28]
Zhang J, Xie J, Li H, et al. Genomic and Phenotypic Evolution of Tigecycline-Resistant Acinetobacter baumannii in Critically Ill Patients[J]. Microbiol Spectr, 2022, 10(1): e159321.
[29]
Lucassen K, Muller C, Wille J, et al. Prevalence of RND efflux pump regulator variants associated with tigecycline resistance in carbapenem-resistant Acinetobacter baumannii from a worldwide survey[J]. J Antimicrob Chemother, 2021, 76(7): 1724-1730.
[30]
Trebosc V, Gartenmann S, Tötzl M, et al. Dissecting Colistin Resistance Mechanisms in Extensively Drug-Resistant Acinetobacter baumannii Clinical Isolates[J]. mBio, 2019, 10(4): e01083-19.
[31]
Sun B, Liu H, Jiang Y, et al. New Mutations Involved in Colistin Resistance in Acinetobacter baumannii[J]. mSphere, 2020, 5(2): e00895-19.
[32]
Hussein NH, Al-Kadmy IMS, Taha BM, et al. Mobilized colistin resistance (mcr) genes from 1 to 10: a comprehensive review[J]. Mol Biol Rep, 2021, 48(3): 2897-2907.
[33]
Thi Khanh Nhu N, Riordan DW, Do Hoang Nhu T, et al. The induction and identification of novel Colistin resistance mutations in Acinetobacter baumannii and their implications[J]. Sci Rep, 2016, 6: 28291.
[34]
Lin MF, Lin YY, Lan CY. Contribution of EmrAB efflux pumps to colistin resistance in Acinetobacter baumannii[J]. J Microbiol, 2017, 55(2): 130-136.
[35]
D′Souza R, Pinto NA, Phuong NL, et al. Phenotypic and Genotypic Characterization of Acinetobacter spp. Panel Strains: A Cornerstone to Facilitate Antimicrobial Development[J]. Front Microbiol, 2019, 10: 559.
[36]
Nogbou ND, Nkawane GM, Ntshane K, et al. Efflux Pump Activity and Mutations Driving Multidrug Resistance in Acinetobacter baumannii at a Tertiary Hospital in Pretoria, South Africa[J]. Int J Microbiol, 2021, 2021: 9923816.
[37]
Zaki MES, Abou EN, Mofreh M. Molecular Study of Quinolone Resistance Determining Regions of gyrA Gene and parC Genes in Clinical Isolates of Acintobacter baumannii Resistant to Fluoroquinolone[J]. Open Microbiol J, 2018, 12: 116-122.
[38]
Mohammed MA, Salim MTA, Anwer BE, et al. Impact of target site mutations and plasmid associated resistance genes acquisition on resistance of Acinetobacter baumannii to fluoroquinolones[J]. Sci Rep, 2021, 11(1): 20136.
[39]
Roy S, Chatterjee S, Bhattacharjee A, et al. Overexpression of Efflux Pumps, Mutations in the Pumps' Regulators, Chromosomal Mutations, and AAC(6′)-Ib-cr Are Associated With Fluoroquinolone Resistance in Diverse Sequence Types of Neonatal Septicaemic Acinetobacter baumannii: A 7-Year Single Center Study[J]. Front Microbiol, 2021, 12: 602724.
[40]
Okada U, Yamashita E, Neuberger A, et al. Crystal structure of tripartite-type ABC transporter MacB from Acinetobacter baumannii[J]. Nat Commun, 2017, 8(1): 1336.
[41]
Martinez-Trejo A, Ruiz-Ruiz JM, Gonzalez-Avila LU, et al. Evasion of Antimicrobial Activity in Acinetobacter baumannii by Target Site Modifications: An Effective Resistance Mechanism[J]. Int J Mol Sci, 2022, 23(12): 6582.
[42]
Girija ASS, Vijayashree Priyadharsini J, Paramasivam A. Plasmid-encoded resistance to trimethoprim/sulfamethoxazole mediated by dfrA1, dfrA5, sul1 and sul2 among Acinetobacter baumannii isolated from urine samples of patients with severe urinary tract infection[J]. J Glob Antimicrob Resist, 2019, 17: 145-146.
[1] 李培杰, 乔永杰, 张浩强, 曾健康, 谭飞, 李嘉欢, 王静, 周胜虎. 细菌培养阴性的假体周围感染诊治的最新进展[J]. 中华关节外科杂志(电子版), 2023, 17(06): 827-833.
[2] 涂家金, 廖武强, 刘金晶, 涂志鹏, 毛远桂. 严重烧伤患者鲍曼不动杆菌血流感染的危险因素及预后分析[J]. 中华损伤与修复杂志(电子版), 2023, 18(06): 491-497.
[3] 廖锵云, 王震, 林洁玉, 廖夏, 邓锦华, 李杰峰, 邓建维, 李明, 荣新洲. 虎门地区创伤弧菌感染的临床观察[J]. 中华损伤与修复杂志(电子版), 2023, 18(05): 394-398.
[4] 蔡柔妹, 曾洁梅, 黄伟丽, 谢文敏, 刘燕丹, 吴漫君, 蔡楚燕. 利用QC小组干预降低经烧伤创面股静脉置管导管相关性感染发生率的临床观察[J]. 中华损伤与修复杂志(电子版), 2023, 18(05): 399-404.
[5] 杨瑞洲, 李国栋, 吴向阳. 腹股沟疝术后感染的治疗方法探讨[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 715-719.
[6] 徐金林, 陈征. 抗菌药物临床应用监测对腹股沟疝修补术预防用药及感染的影响[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 720-723.
[7] 李静如, 王江玲, 吴向阳. 简易负压引流在腹股沟疝术后浅部感染中的疗效分析[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 745-749.
[8] 李秉林, 吕少诚, 潘飞, 姜涛, 樊华, 寇建涛, 贺强, 郎韧. 供肝灌注液病原菌与肝移植术后早期感染的相关性分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 656-660.
[9] 赵立力, 王魁向, 张小冲, 李志远. 血沉与C-反应蛋白比值在假体周围感染中的诊断价值分析[J]. 中华老年骨科与康复电子杂志, 2023, 09(06): 351-355.
[10] 卓少宏, 林秀玲, 周翠梅, 熊卫莲, 马兴灶. CD64指数、SAA/CRP、PCT联合检测在小儿消化道感染性疾病鉴别诊断中的应用[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 505-509.
[11] 李静静, 翟蕾, 赵海平, 郑波. 多囊肾合并囊肿的多重耐药菌感染一例并文献复习[J]. 中华临床医师杂志(电子版), 2023, 17(08): 920-923.
[12] 李达, 张大涯, 陈润祥, 张晓冬, 黄士美, 陈晨, 曾凡, 陈世锔, 白飞虎. 海南省东方市幽门螺杆菌感染现状的调查与相关危险因素分析[J]. 中华临床医师杂志(电子版), 2023, 17(08): 858-864.
[13] 卓徐鹏, 刘颖, 任菁菁. 感染性疾病与老年人低蛋白血症的相关性研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 896-899.
[14] 李琪, 黄钟莹, 袁平, 关振鹏. 基于某三级医院的ICU多重耐药菌医院感染影响因素的分析[J]. 中华临床医师杂志(电子版), 2023, 17(07): 777-782.
[15] 杨艳丽, 陈昱, 赵若辰, 杜伟, 马海娟, 许珂, 张莉芸. 系统性红斑狼疮合并血流感染的危险因素及细菌学分析[J]. 中华临床医师杂志(电子版), 2023, 17(06): 694-699.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号